NCT06566391 2024-08-22
Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
European Institute of Oncology
Phase 2 Unknown
Clinical Trials
15 trialsNCT03068624 2024-01-25
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
M.D. Anderson Cancer Center
Phase 1 Unknown
NCT02977052 2023-11-15
OpACIN-neo
The Netherlands Cancer Institute
Phase 2 Unknown
NCT03528408 2023-04-11
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
Hoosier Cancer Research Network
Phase 2 Unknown
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT02437279 2022-04-15
OpACIN
The Netherlands Cancer Institute
Phase 1 Unknown
NCT03161756 2022-04-07
CHARLI
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Unknown
NCT04860076 2021-04-26
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Asylia Diagnostics BV
Unknown
NCT02913417 2021-04-19
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
California Pacific Medical Center Research Institute
Phase 1/2 Unknown
NCT04136470 2020-08-10
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
Ardigen
Unknown
NCT04250246 2020-01-31
NIBIT-ML1
Italian Network for Tumor Biotherapy Foundation
Phase 2 Unknown
NCT04169867 2019-11-20
Polish Microbiome Map
Ardigen
Unknown
NCT03098160 2017-10-30
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
Threshold Pharmaceuticals
Phase 1 Unknown
NCT01565837 2016-02-01
SART
Comprehensive Cancer Centers of Nevada
Phase 2 Unknown
NCT02608437 2015-11-18
NIBIT-M4
Italian Network for Tumor Biotherapy Foundation
Phase 1 Unknown